volume 21 issue 4 pages 309-322

Temporins: An Approach of Potential Pharmaceutic Candidates

Stella González Romero 1
Alejandra Beatriz Cardillo 2, 3
María Camila Martínez Ceron 2, 3
Silvia Andrea Camperi 2, 3
Silvana Laura Giudicessi 2, 3
Publication typeJournal Article
Publication date2019-12-05
scimago Q2
wos Q3
SJR0.587
CiteScore3.6
Impact factor1.4
ISSN10962964, 15578674
PubMed ID:  31804896
Microbiology (medical)
Infectious Diseases
Surgery
Abstract
Antimicrobial peptides (AMPs), also known as host defense peptides, are small and mostly polycationic molecules that form part of the innate immune response. There are currently more than 3000 experimentally reported AMPs. Particularly in frogs, the temporin family has been discovered as potential AMPs. The aim of this work is to review the latest publications about this class of peptides, discuss their properties, and present an update of the last studies and new discoveries in the field. More than 130 temporins have been identified in this family. The most studied temporins are temporin A (TA), temporin B (TB), and temporin L (TL). These peptides showed antimicrobial activity against gram-negative, gram-positive bacteria and fungi. Since the discovery of temporins in 1996, several groups of researchers isolated different peptides from various species of frogs that were included as members of this family. Although antimicrobial activity of many temporins has not been analyzed yet, most of them showed antimicrobial and antifungal activities. A combination of nanotechnology and AMPs for temporins in different antimicrobial treatments could be a promising alternative for resistant pathogens. These studies demonstrate that, even with the advancement in scientific research on the composition and antimicrobial activity of temporins, further studies are necessary to wholly understand their components and mechanisms of action.
Found 
Found 

Top-30

Journals

1
2
3
4
5
6
7
8
9
Antibiotics
9 publications, 18.37%
International Journal of Molecular Sciences
7 publications, 14.29%
Journal of Medicinal Chemistry
3 publications, 6.12%
Pharmaceutics
2 publications, 4.08%
Amino Acids
2 publications, 4.08%
Journal of the American Society for Mass Spectrometry
1 publication, 2.04%
Analytical and Bioanalytical Chemistry
1 publication, 2.04%
Journal of Fungi
1 publication, 2.04%
Frontiers in Molecular Biosciences
1 publication, 2.04%
Toxins
1 publication, 2.04%
Biochemical Pharmacology
1 publication, 2.04%
Biomolecules
1 publication, 2.04%
Biochimie
1 publication, 2.04%
Chemical Biology and Drug Design
1 publication, 2.04%
Biochemistry
1 publication, 2.04%
Dalton Transactions
1 publication, 2.04%
Journal of Enzyme Inhibition and Medicinal Chemistry
1 publication, 2.04%
Journal of Analytical Chemistry
1 publication, 2.04%
International Journal of Peptide Research and Therapeutics
1 publication, 2.04%
Journal of the American Chemical Society
1 publication, 2.04%
Expert Opinion on Drug Delivery
1 publication, 2.04%
Molecules
1 publication, 2.04%
Peptide Science
1 publication, 2.04%
Scientific Reports
1 publication, 2.04%
Journal of Peptide Science
1 publication, 2.04%
Bioinformatics
1 publication, 2.04%
Protein and Peptide Letters
1 publication, 2.04%
Critical Reviews in Biotechnology
1 publication, 2.04%
Mass Spectrometry
1 publication, 2.04%
1
2
3
4
5
6
7
8
9

Publishers

5
10
15
20
25
MDPI
22 publications, 44.9%
American Chemical Society (ACS)
6 publications, 12.24%
Springer Nature
5 publications, 10.2%
Wiley
4 publications, 8.16%
Taylor & Francis
3 publications, 6.12%
Elsevier
2 publications, 4.08%
Frontiers Media S.A.
1 publication, 2.04%
Royal Society of Chemistry (RSC)
1 publication, 2.04%
Pleiades Publishing
1 publication, 2.04%
Cold Spring Harbor Laboratory
1 publication, 2.04%
Oxford University Press
1 publication, 2.04%
Bentham Science Publishers Ltd.
1 publication, 2.04%
The Mass Spectrometry Society of Japan
1 publication, 2.04%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
49
Share
Cite this
GOST |
Cite this
GOST Copy
González Romero S. et al. Temporins: An Approach of Potential Pharmaceutic Candidates // Surgical Infections. 2019. Vol. 21. No. 4. pp. 309-322.
GOST all authors (up to 50) Copy
González Romero S., Cardillo A. B., Martínez Ceron M. C., Camperi S. A., Giudicessi S. L. Temporins: An Approach of Potential Pharmaceutic Candidates // Surgical Infections. 2019. Vol. 21. No. 4. pp. 309-322.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1089/sur.2019.266
UR - https://doi.org/10.1089/sur.2019.266
TI - Temporins: An Approach of Potential Pharmaceutic Candidates
T2 - Surgical Infections
AU - González Romero, Stella
AU - Cardillo, Alejandra Beatriz
AU - Martínez Ceron, María Camila
AU - Camperi, Silvia Andrea
AU - Giudicessi, Silvana Laura
PY - 2019
DA - 2019/12/05
PB - Mary Ann Liebert
SP - 309-322
IS - 4
VL - 21
PMID - 31804896
SN - 1096-2964
SN - 1557-8674
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2019_González Romero,
author = {Stella González Romero and Alejandra Beatriz Cardillo and María Camila Martínez Ceron and Silvia Andrea Camperi and Silvana Laura Giudicessi},
title = {Temporins: An Approach of Potential Pharmaceutic Candidates},
journal = {Surgical Infections},
year = {2019},
volume = {21},
publisher = {Mary Ann Liebert},
month = {dec},
url = {https://doi.org/10.1089/sur.2019.266},
number = {4},
pages = {309--322},
doi = {10.1089/sur.2019.266}
}
MLA
Cite this
MLA Copy
González Romero, Stella, et al. “Temporins: An Approach of Potential Pharmaceutic Candidates.” Surgical Infections, vol. 21, no. 4, Dec. 2019, pp. 309-322. https://doi.org/10.1089/sur.2019.266.